Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Mar 2025
Army bomb disposal veterans may have a significantly increased risk of developing bladder cancer compared to the general public, according to a newly published study.
Read Full NewsA novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.
Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.
Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.
Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.
A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.
People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.
Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.
1.
Early Results for Anorexia Nervosa with Psilocybin.
2.
Vaccine shows promise for pancreatic cancer, study finds
3.
Mindfulness-based interventions are advised by cancer organizations to treat patients' anxiety and depression.
4.
Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.
5.
Rural-urban disparities seen in cervical cancer
1.
Innovative Practices in Hematology in the Digital Era
2.
Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
5.
Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge